← All Kiniksa Pharmaceuticals International, PLC filings

Kiniksa Pharmaceuticals International, PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KNSA
Kiniksa Pharmaceuticals International, PLC
10-K: Kiniksa Pharmaceuticals Reports Strong 2025 Revenue Growth
Kiniksa Pharmaceuticals International, plc reported significant product revenue growth in 2025, driven by ARCALYST sales, while advancing its pipeline with KPL-387 and KPL-1161.
NASDAQ
KNSA
Kiniksa Pharmaceuticals International, PLC
10-K: Kiniksa Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Kiniksa Pharmaceuticals reported a net loss for 2024, driven by increased operating expenses, despite significant revenue growth from its lead asset, ARCALYST.
NASDAQ
KNSA
Kiniksa Pharmaceuticals International, PLC
10-K: Kiniksa Pharmaceuticals Reports Full Year 2023 Results, Highlights Progress in Key Programs
Kiniksa Pharmaceuticals reports its full year 2023 financial results, showcasing revenue growth and advancements in its clinical programs.